Isatuximab, Carfilzomib, and Dexamethasone Combined With Late Autologous Stem Cell Transplantation: A Synergistic Strategy for First Relapse Multiple Myeloma

Documenti analoghi

• Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
  di: Danilo De Novellis, et al.
  Pubblicazione: (2024)
• Secondary Malignancies After Autologous Stem Cell Transplantations in Patients With Malignant Lymphoma and Multiple Myeloma
  di: Bernd Metzner, et al.
  Pubblicazione: (2024)
• Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial
  di: Paul Richardson, et al.
  Pubblicazione: (2025)
• Allogeneic Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma—A Retrospective Multicenter Analysis
  di: T. Richardson, et al.
  Pubblicazione: (2024)
• Reduced Intensity Conditioning Prior Autologous Stem Cell Transplantation in Elderly DLBCL Patients
  di: Tim Strüßmann, et al.
  Pubblicazione: (2024)